These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35230518)

  • 41. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
    Hickey RM; Lewandowski RJ; Salem R
    Semin Nucl Med; 2016 Mar; 46(2):105-8. PubMed ID: 26897714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 45. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
    Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
    J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of Hepatocellular Carcinoma Response to
    Hectors SJ; Lewis S; Kennedy P; Bane O; Said D; Segall M; Schwartz M; Kim E; Taouli B
    Radiol Imaging Cancer; 2020 Jul; 2(4):e190094. PubMed ID: 32803165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy.
    Ghani MA; Fereydooni A; Chen E; Letzen B; Laage-Gaupp F; Nezami N; Deng Y; Gan G; Thakur V; Lin M; Papademetris X; Schernthaner RE; Huber S; Chapiro J; Hong K; Georgiades C
    Eur Radiol; 2021 Dec; 31(12):8858-8867. PubMed ID: 34061209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm.
    Kim HC; Kim YJ; Lee JH; Suh KS; Chung JW
    J Vasc Interv Radiol; 2019 Jan; 30(1):1-8. PubMed ID: 30293734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.
    Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS
    J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.
    Monsky WL; Garza AS; Kim I; Loh S; Lin TC; Li CS; Fisher J; Sandhu P; Sidhar V; Chaudhari AJ; Lin F; Deutsch LS; Badawi RD
    Cardiovasc Intervent Radiol; 2011 Apr; 34(2):306-18. PubMed ID: 20683722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
    Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
    Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma.
    Chan KT; Alessio AM; Johnson GE; Vaidya S; Kwan SW; Monsky W; Wilson AE; Lewis DH; Padia SA
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):358-365. PubMed ID: 29559288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
    Levillain H; Duran Derijckere I; Ameye L; Guiot T; Braat A; Meyer C; Vanderlinden B; Reynaert N; Hendlisz A; Lam M; Deroose CM; Ahmadzadehfar H; Flamen P
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2270-2279. PubMed ID: 31324943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
    Xing M; Kokabi N; Camacho JC; Kim HS
    BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
    D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
    Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.
    Jia Z; Jiang G; Tian F; Zhu C; Qin X
    Saudi J Gastroenterol; 2016; 22(5):353-359. PubMed ID: 27748320
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization.
    Ibrahim SM; Kulik L; Baker T; Ryu RK; Mulcahy MF; Abecassis M; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1094-101. PubMed ID: 22069121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.